News | January 20, 2015

University of Tennessee Engineering Research Offers Hope for Heart Valve Patients

Teams working to create calcification-proof tissue-engineered heart valves

Tennessee, Knoxville, heart valve, tissue engineered, calcification proof

January 20, 2015 — There could soon be new hope for those facing one of humanity's biggest health issues, thanks to research from the University of Tennessee Knoxville College of Engineering. 

Cardiovascular diseases are the world's number one cause of death, with some estimates indicating that as many as one-third of the planet's deaths in a given year are attributable to some form of the disease. 

While heart valve disease is only one of many afflictions falling under that heading, its widespread impact — affecting up to 30 percent of the elderly population in developed countries alone — makes it a key component of the overall problem of heart-related ailments.

Zannatul Ferdous, an assistant professor in UT's Department of Mechanical, Aerospace, and Biomedical Engineering, leads a research team addressing the issue, thanks in part to a BRIGE — Broadening Participation Research Initiation Grants in Engineering — grant from the National Science Foundation.

"Currently, the treatment option for valve disease is mainly end-stage replacement or repair surgeries, and no early treatment or detection options exist," said Ferdous. "The goal of our lab is to understand these diseases and develop alternate treatment options such as functional tissue-engineered heart valves."

One of the main issues with heart valves that the group is focusing on is what is known as calcification, a process where calcium deposits build up on the valves, eventually restricting the flow of blood through the heart. 

By studying the root causes of calcification and constructing new heart valves through tissue engineering — using cells to construct organic human tissue — Ferdous and her group aim to eventually develop calcification-proof valves. 

“We are tackling calcification head-on, looking at risk factors from everything like age and gender to chemical factors and cell characteristics," said Ferdous. "At the same time, we are developing custom devices that will allow us to truly mimic all the forces at play in the heart.”

For more information: www.mabe.utk.edu

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init